GSK plc (GSK, GSK.L) has announced positive headline results from its MATINEE phase III clinical trial, which assessed the efficacy of Nucala (mepolizumab), a monoclonal antibody targeting interleukin-5 (IL-5), in adults with chronic obstructive pulmonary disease (COPD).The trial successfully met its primary endpoint. When Nucala was added to inhaled maintenance therapy, the results indicated a statistically significant and clinically meaningful reduction in the annual rate of moderate to severe exacerbations compared to placebo, with patients treated over a period of up to 104 weeks.Preliminary safety data align with Nucala’s established safety profile, although further analysis of the results is still in progress.Mepolizumab, first approved in the U.S. in 2015 for severe asthma with an eosinophilic phenotype, is a monoclonal antibody that binds to and inhibits interleukin-5 (IL-5), a crucial cytokine in type 2 inflammation. Nucala has since been developed for treating a variety of IL-5 mediated diseases linked to type 2 inflammation.The material has been provided by InstaForex Company – www.instaforex.com
- U.S. Import Prices Dip Slightly More Than Expected In August - September 13, 2024
- Tenon Medical Prices $4.5 Mln Public Offering Of Shares, Pre-market Stock Soars Over 177% - September 13, 2024
- Kaixin: Nasdaq Panel Grants Temporary Exception To Bid Price Rule - September 13, 2024
